Arcutis Biotherapeutics, Inc. (ARQT) Tops Q4 EPS by 19c

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q4 EPS of ($0.09), $0.19 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $71.3 million versus the consensus estimate of $54.72 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• Putin Said To Plan Ukraine Escalation, Seeing Talks Fruitless - Bloomberg
• Abercrombie & Fitch (ANF) Tops Q2 EPS by $2.19, Offers Guidance
• Electromed (ELMD) PT Raised to $50 at Freedom Broker